| Company Name | Exchange | Ticker | Last Price | Day 1 (% Change) | Day 2 (% Change) | 52 WEEK HIGH | 52 WEEK LOW | Last Volume | M.Cap MM ($) |
| Verso Paper Corp | NYSE | VRS | 4.38 | 393.8% | 36.4% | 5.55 | 0.52 | 12,839,759 | 232.9 |
| Microbix Biosystems Inc | TSX | MBX | 0.29 | 25.0% | 14.0% | 0.29 | 0.12 | 157,400 | 19.0 |
Verso Paper Corp (NYSE: VRS), engaged in producing coated free-sheet,
coated ground-wood, and uncoated super-calendared papers, gained over 574%
during its past two trading sessions gaining more than 36% in each of the
two consecutive days. During its last trading session, the stock gained
36.4% and closed touching its 52-week high of $4.38 with significant trading
volume of 12.9 million shares. During its past 5-trading sessions, VRS
gained 595.2% with 5-day average volume of 3.9 million shares compared
to 1-month daily average volume of 682,096 shares. The stock skyrocketed
after VRS announced to buy a privately held New Page Holdings Inc for about
$900 million in cash and bonds to form a more cost-efficient company that
can cope with increasing pressure from digital media.
Microbix Biosystems Inc (TSX: MBX), a Canada-based biotechnology company
engaged in research and development, and commercialization of biological
products and technologies, gained over 43% during its past two trading
sessions gaining more than 14% in each of the two consecutive days. During
its last trading session, the stock gained 14% and closed at its 52-week
high of C$0.29 with significant trading volume of 157,400 shares. During
its past 5-trading sessions, MBX gained 72.7% with 5-day average volume
of 84,395 shares compared to 1-month daily average volume of 46,544 shares.
Recently, MBX sued Novartis Vaccines and Diagnostics alleging infringement
of its proprietary VIRUSMAX technology. VIRUSMAX technology is useful for
increasing virus yields in egg-based vaccine manufacture.
